Straits Times Index
3,344.82 +14.01 (+0.42%) Nikkei
38,605.07 -98.44 (-0.25%) Hang Seng
18,399.04 -77.76 (-0.42%) FTSE 100
8,285.34 +38.39 (+0.47%) Bitcoin USD
71,222.23 +177.48 (+0.25%) CMC Crypto 200
1,482.94 -41.86 (-2.75%)
Syndax Pharmaceuticals Inc (1T3.BE)
- PR Newswire
Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has advanced into the Phase 1b portion of its Phase 1/2 proof-of-concept trial of revumenib, the Company's highly selective, oral menin inhibitor, as a monotherapy in patients with relapsed or refractory (R/R) metastatic microsatellite stable (MSS) colorectal cancer (CRC). The Company's decision was supported by the trial's Independent D
- PR Newswire
Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 8:40 a.m. ET.
- PR Newswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on June 1, 2024 the Company granted inducement awards to purchase up to 499,200 shares of common stock to fifty-three new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the un
